Literature DB >> 7000903

Biochemical and biologic characterization of lymphocyte regulatory molecules. IV. Purification of Interleukin 2 from a murine T cell lymphoma.

D Mochizuki, J Watson, S Gillis.   

Abstract

A cloned murine T cell line, LBRM-33 5A4, growing in culture can be activated by phytohemagglutinin (PHA) to secrete Interleukin 2 (IL-2) activity. In the absence of PHA, LBRM cells do not produce IL-2. The chemical and biologic properties of LBRM-derived IL-2 are compared to those of murine spleen-derived IL-2. The fractionation of culture supernatants from PHA-activated LBRM cells by ion-exchange chromatography, gel filtration, and isoelectric focusing (IEF) reveals that IL-2 activity is contained in a class of molecules indistinguishable in size (30,000) and charge (pI 4.3-4.7 and 4.9-5.1) from murine spleen IL-2. LBRM-derived IL-2 also exhibits the entire spectrum of biologic activities exhibited by spleen IL-2, stimulating the growth of established T cell lines in culture, the generation of cytotoxic T lymphocytes in thymocyte cultures and the induction of antibody responses in nude spleen cultures. Both LBRM and splenic-derived IL-2 activities exhibit similar properties after digestion with proteases, and various chemical and temperature treatments. Since IL-2 is derived from a cloned cell line, it is likely these lymphocyte assays are detecting a single class of molecules that act directly on activated T cells. The use of LBRM cells as a source of IL-2 should greatly facilitate studies on the molecular characterization and biologic activity of this class of lymphocyte regulatory molecules.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7000903

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Conditioned medium from concanavalin A-stimulated spleen cells inhibits the IgE-dependent sensitization of murine peritoneal mast cells in vitro.

Authors:  J W Coleman
Journal:  Immunology       Date:  1990-01       Impact factor: 7.397

2.  The analysis of an anti-fluorescein response at limit dilution: the effect of lymphokine preparations on the apparent specificity.

Authors:  M A Skinner; R Prestidge; J Marbrook
Journal:  Immunology       Date:  1985-07       Impact factor: 7.397

3.  The effect of 2'deoxyguanosine on human lymphocyte responses. I. 2'deoxyguanosine enhances T lymphocyte responses.

Authors:  A C Hanglow; P M Lydyard
Journal:  Clin Exp Immunol       Date:  1985-03       Impact factor: 4.330

Review 4.  [The role of interleukin-2 during the activation of cytotoxic T-lymphocytes].

Authors:  W Solbach; M Röllinghoff; H Wagner
Journal:  Klin Wochenschr       Date:  1983-01-17

5.  Lipoteichoic acid inhibits interleukin-2 (IL-2) function by direct binding to IL-2.

Authors:  L M Plitnick; R A Jordan; J A Banas; D M Jelley-Gibbs; M C Walsh; M T Preissler; E J Gosselin
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

6.  Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

Authors:  M A Cheever; P D Greenberg; A Fefer; S Gillis
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

7.  Correlated expression of T cell growth factor dependence, sensitivity to Vicia villosa lectin, and cytolytic activity in hybrids between cytolytic T cells and T lymphomas.

Authors:  A Conzelmann; A Silva; M Cianfriglia; C Tougne; R P Sekaly; M Nabholz
Journal:  J Exp Med       Date:  1982-11-01       Impact factor: 14.307

8.  In vivo modulation of thymus-derived lymphocytes with monoclonal antibodies in mice. III. Spontaneous and natural cytotoxic effector cells.

Authors:  A G Herbert; G S Le Gros; S Bidawid; J D Watson
Journal:  Immunology       Date:  1984-02       Impact factor: 7.397

9.  Tunicamycin treatment inhibits the antiviral activity of interferon in mice.

Authors:  R K Maheshwari; M M Husain; A M Attallah; R M Friedman
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

10.  Tumour inhibitory effects of TCGF/IL-2/-containing preparations.

Authors:  J Bubeník; M Indrová; P Perlmann; K Berzins; O Mach; J Kraml; A Toulcová
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.